Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma

Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma

BackgroundThe large-scale proteomic platform known as the SomaScan® assay is capable of simultaneously measuring thousands of proteins in patient specimens through next-generation aptamer-based multiplexed technology. While previous studies have utilized patient peripheral blood to suggest serum bio...

Full description

Saved in:
Bibliographic Details
Main Authors: Ryan A. Lacinski, Sebastian A. Dziadowicz, Clark A. Roth, Li Ma, Vincent K. Melemai, Brody Fitzpatrick, Edwin Chaharbakhshi, Tanya Heim, Ines Lohse, Karen E. Schoedel, Gangqing Hu, Nicolas J. Llosa, Kurt R. Weiss, Brock A. Lindsey
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Oncology
Subjects:
osteosarcoma
plasma
proteomics
transcobalamin-II
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1417459/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items